Generex Biotechnology Corp. (fka GNBTQ)

[WeeZuhl]

There are assets here worth acquiring...


1. Buccal drug delivery platform.
----A. "OraLyn" for insulin
----B. "RapidMist" for marijuana, etc.

2. Ii-key immune system activation tag for vaccination, "Antigen Express".
----A. AE-37 (promising data in difficult to treat "triple negative" breast cancer).
----B. Applicable for rapid vaccine development for influenza, Ebola, etc.




Generex with Mark Fletcher as CEO will never, ever make anything of any of these assets, but the assets are nonetheless real, promising, patented, and deserving of ongoing development. Fletcher may be an incompetent CEO, but he does own a lot of shares. My hope is that Fletcher's desire for Personal Enrichment will result in some sort of deal for these assets prior to BK instead of after BK. If not, then why bother to issue an "Annual" Report? Wasn't it intersting that there was a spike in volume on Friday even though the report was not filed until after market close? Somebody acquired 10 million shares between .005 and .008 last year (including some of mine). Somebody knows something. I'm not buying this turd, but I do have decent stash of bagholder shares that I'm willing to hold as an all or nothing speculative bet. Buyer (holder) beware.




https://www.ncbi.nlm.nih.gov/pubmed/27029708

In patients with triple-negative breast cancer (HER2 IHC 1+/2+ and hormone receptor negative) DFS was 77.7% in vaccinated patients (n = 25) versus 49.0% in control patients (n = 25) (P = 0.12).